Lipid bodies are non-membrane-bound, lipid-rich cytoplasmic inclusions that occur in many mammalian cell types. Because lipid bodies are more prominent in cells associated with inflammation and are repositories of arachidonylphospholipids, a role for lipid bodies in the oxidative metabolism of arachidonic acid to form eicosanoids has been suggested. To evaluate further whether lipid bodies, in addition to serving as non-membranous sources of substrate arachidonate, are involved in eicosanoid formation, we used cells isolated from human lung to investigate the intracellular localization of prostaglandin endoperoxide (PGH) synthase (cyclmxygenase), the key initial, rate-limiting enzyme in the formation of prostaglandins and thromboxanes. Isolated lung cells containing a mixture of mast cells, alveolar macrophages, Type 11 alveolar pneumocytes, and neutrophils from short-term cultures were fted in suspension in a dilute aldehyde mixture, post-fixed in osmium tetroxide, stained en bloc with uranyl acetate, dehydrated in a graded series of alcohols, and embedded in Epon. A post-embedding immunogold procedure was used with a primary PGH synthase monoclonal antibody and 20-nm gold-conjugated sec-Supported by USPHS grants AI-33372, AI-22571, AI-20241. ondary antibody to demonstrate enzyme locations. Specificity controls were also done. We found PGH synthase in lipid bodies of human lung mast cells, alveolar macrophages, Type II alveolar pneumocytes, and neutrophils. Specifc seaetory and lysosomal granules and plasma membranes did not express PGH synthase. Specificity controls, including omission of the primary antibody or substitution with an irrelevant antibody, were negative. Absorption of the specific PGH synthase antibody with purified solid-phase PGH synthase resulted in a marked reduction of label in lipid bodies of all four cell types. These findings establish the presence of PGH synthase in lipid bodies of human lung mast cells, alveolar maaophages, Type II alveolar pneumocytes, and neutrophils and, in concert with previous studies, suggest that these cytoplasmic lipid-rich organelles may be non-membrane sites of eicosanoid formation. ( JHisrochem Cyrochem  40:759-769, i992) 
Introduction
Lipid bodies, which are found in multiple cell types, are distinct cytoplasmic organelles that have previously been regarded as neutral lipid depots (1) . Newly emerging data, however, indicate that lipid bodies may have a role in the oxidative formation of eicosa-noids (2-4). Eicosanoids are synthesized from substrate arachidonic acid that is esterified principally within phospholipids of cells. These arachidonyl-phospholipids are generally believed to reside solely within cell membranes, and membranes are considered to serve both as repositories of arachidonate storage and as sites of synthesis of arachidonate-derived eicosanoids.
Our interest in lipid bodies as organelles involved in eicosanoid formation is based on a series of findings, including initial morphological observations. First, lipid bodies are widely distributed in mammalian cells, many of which are known to participate in the generation of eicosanoids ( 5 ) . Second, lipid bodies characteristi-cally increase in cells as they participate in a wide variety of acute, subacute, and chronic inflammatory processes in tissues (5) . Third, cells that demonstrate increased lipid bodies are not damaged, using ultrastructural morphological criteria (5). These morphological observations indicate that lipid body formation in vivo represents a morphological correlate for cells participating in inflammation. Additional insights into the formation of lipid bodies were derived from studies with human neutrophils (6,7). Lipid bodies, morphologically identical to those present in reactive tissue neutrophils in vivo, could be induced to form de novo within minutes by exposure of cells to &unsaturated fatty acids (6.7). In addition to cis fatty acids, other activators of protein kinase C, including cellpermeant diglycerides and specific phorbol esters, induced lipid body formation, whereas inhibitors of protein kinase C (i.e., H-7, staurosporine, and 1-O-hexadecyl-2-O-methyl-rac-glycero1) inhibited lipid body formation in neutrophils induced by cis fatty acids and other protein kinase C activators (7). Thus, lipid body formation within cells represents a concerted cell response, mediated by protein kinase C activation, which develops in diverse cells associated with varied inflammatory responses.
A role for lipid bodies as repositories of substrate arachidonic acid available for eicosanoid formation has been suggested from ultrastructural and biochemical studies with a number of cell types (reviewed in refs. 2-4). Early observations indicated that a variety of 3H-labeled lipid synthetic precursors, including palmitic acid, methylcholine, and myoinositol, could be localized to lipid bodies in ultrastructural autoradiographic studies of cultured guinea pig peritoneal macrophages (8). Direct demonstration that the specific arachidonate fatty acid precursor for eicosanoid synthesis by either the lipoxygenase or the cyclooxygenase pathway was localized in lipid bodies was obtained from ultrastructural autoradiographic localization of cell-incorporated [ 3H]-arachidonate.
[ 3H]-Arachidonate incorporation within lipid bodies was found in guinea pig, mouse, and human macrophages (9). human lung mast cells (9), human neutrophils (2,6), human ciliated respiratory epithelial cells (2), guinea pig Line 10 hepatoma cells (2), mouse peritoneal lymphoblasts (2), and human eosinophils (10). Biochemical analysis of total cell lipids indicated that the [3H]-arachidonate in lipid bodies was not free fatty acid, but rather was esterified in glycerolipids. In human lung mast cells, most [ 3H]-arachidonate was in neutral lipids (11), whereas in mouse peritoneal macrophages (9,12), human neutrophils (6), and eosinophils (10) most [ 3H]arachidonate was esterified in phospholipid classes. Lipid bodies isolated by subcellular fractionation from guinea pig peritoneal macrophages and Line 10 hepatocarcinoma cells (A.M. Dvorak et al., unpublished data) and human eosinophils (13) contained incorporated [3H]-arachidonate, demonstrable by autoradiography. Most directly, with lipid bodies isolated free of cell membranes by subcellular fractionation of lipid body-rich human eosinophils, most [ 3H]-arachidonate incorporated within lipid bodies was shown to reside in phospholipid classes, including the same proportions of phosphatidylcholine, phosphatidylinositol, and phosphatidylethanol-amine/phosphatidylserine as [ 3H]-arachidonate labeled in cell membranes (13). Therefore, lipid bodies are major intracellular sites of incorporation of arachidonate, which is largely present in the form of arachidonyl-phospholipids.
if arachidonyl-phospholipids present in lipid bodies are to provide substrate for the formation of eicosanoids, such lipids must either be translocated to cell membranes for eicosanoid formation or be acted on locally at lipid body sites. That enzymatic activities reside in lipid bodies has been indicated by the regular demonstration of endogenous peroxidase andlor nonspecific esterase in lipid bodies of human lung mast cells (3), guinea pig tumor cells (2), human eosinophils (14-17), human monocytes (14), guinea pig basophils (3, 18) , cultured cloned guinea pig endothelial cells (w), human basophils (3, 14, 20, 21) , and human skin histiocytes (17) . Whether this esterase activity might reflect lipolytic enzymes and whether some of the peroxidase activity might be mediated by the peroxidatic function of eicosanoid-forming enzymes [e.g., prostaglandin endoperoxide (PGH) synthase (22)] has not been ascertained. PGH synthase, also referred to as cyclooxygenase, is the initial rate-limiting enzyme in the cyclooxygenase pathway of synthesis of prostacyclin, thromboxanes, and prostaglandins. Evidence that this key eicosanoid-forming enzyme resides in lipid bodies has been found in biochemical and immunohistochemical studies of lipid bodies from human eosinophils and monocytes and murine 3T3 fibroblasts (P.F. Weller, S.W. Ryeom, unpublished data). Because the direct localization of this initial enzyme of the cyclooxygenase pathway (often believed to reside solely in plasma membranes) to lipid bodies would indicate that lipid bodies are both stores of arachidonate and possible sites of eicosanoid synthesis, we have utilized ultrastructural immunogold localization to document that PGH synthase resides in lipid bodies of several cell types obtained from human lung.
Materials and Methods
Cell Isolation and Culture. Human lung tissue remote from tumor sites was obtained at surgery for removal of cancer-containing lungs. Isolated cell preparations were made, partially purified, and cultured for 6 hr as previously described (9, (23) (24) (25) . The resultant samples, enriched for mast cells, also contained alveolar macrophages, Type I1 alveolar pneumocytes and, rarely, neutrophils. Elecuon Microscopic Preparation. Cells cultured for 6 hr were fixed in suspension for 1 hr at 2O' C in a dilute mixture of aldehydes containing glutaraldehyde, paraformaldehyde, and calcium chloride in sodium cacodylate buffer, washed owmight at 4'C in the same buffer, rapidly centrifuged through molten agar to form cell pellets which were then post-fixed in collidine-buffered osmium tetroxide for 2 hr at 2O' C, stained en bloc with uranyl acetate, dehydrated in a graded series of alcohols, infiltrated, embedded and polymerized in a propylene oxide-Epon sequence, all as in previous studies (25).
Post-embedding Immunogold Staining. A large number of preparations were examined, using variations on the finally established method. During these preliminary studies to ascertain the best conditions to use, we identifed sweral important potential technical traps that prevented positive results. These will be discussed later. From these preliminary studies, we established the following protocol and believe it to be the best procedure for the demonstration of PGH synthase in lipid bodies of the four cell types that we examined: (a) thin sections on either gold or nickel grids were unmasked in 2 % sodium metaperiodate (26) for 30 min; (b) three washes of 10 min each in Tris-buffered saline containing 0.1% bovine serum albumin (TBS-BSA); (c) block with TBS-BSA containing 5 % normal goat serum for 60 min; (d) incubate for 60 min at room temperature in 1:20 dilution (in TBS, 0.1% BSA, 1% normal goat serum, 0.1% Tween-20)
of primary mouse monoclonal antibody to PGH synthase (Cayman Chemical; Ann Arbor, MI); (e) three washes for 10 min each, in TBS-BSA; (f) incubate for 60 min at room temperature in 1:20 dilution (in same diluent as primary antibody) of 20-nm gold-labeled goat anti-mouse IgG (EY Laboratories; San Mateo, CA); (g) three washes for 5 min each in TBS-BSA; (h) two washes for 5 min each in distilled water, and dried overnight; (i) stain with dilute lead citrate for 10 min. Technical traps to be avoided include the following. (a) Sections prepared at various times in advance of immunogold staining yielded variable results. After testing several primary and secondary antibody lots, it became apparent that the most important variable was the storage time of thin sections before immunogold staining, not antibody lots. We now use either freshly cut thin sections or thin sections prepared earlier and stored in a vacuum. These sections are good for up to two weeks. (b) Unmasking with sodium metaperiodate (26) is essential for the demonstration of PGH synthase with the post-embedding immunogold procedure. However, the highly osmiophilic lipid bodies distinctive for human lung mast cells are completely dissolved by a standard sodium metaperiodate unmasking procedure (4% for 15-60 min). To partially preserve these fragile structures and to demonstrate PGH synthase within them, we have investigated the unmasking procedure and have arrived at 2% sodium metaperiodate for 30 min as a good compromise for unmasking that allows immunogold labeling to occur in the absence of excessive destruction of human mast cell lipid bodies. Lipid bodies in alveolar macrophages, Type I1 alveolar pneumocytes, and neutrophils all differ from the highly dense lipid bodies in human mast cells in that they are poorly osmiophilic. Consequently, the sodium metaperiodate unmasking procedure did not destroy lipid bodies in these three cell types, and the immunogold procedure for imaging PGH synthase within them was straightforward. Attempts to use unosmicated samples to image human mast cell lipid bodies and, thus to do immunogold stains were also thwarted by a failure to retain sufficient structure in lipid bodies in human mast cells for immunogold analysis. (c) Absorption of the primary anti-PGH synthase antibody with purified ram seminal vesicle PGH synthase (Oxford Biochemical Research; Oxford, MI) (27) in the fluid phase did not work to demonstrate decreased lipid body staining. By contrast, binding of the purified PGH synthase to Immobilon-P (Millipore; Bedford, MA) membranes, followed by blocking of other protein binding sites on the membranes with bovine serum albumin (BSA), provided an efYective source of specifically absorbed antisera (for both anti-PGH synthase and control IgG antibodies) for use in specificity controls for the immunogold procedure. In addition, specific and control antibodies were tested after passage through Immobilon-P membranes that were either blocked or not with BSA alone.
Consols for the Immunogold Method. Three controls werc used to demonstrate specificity of the immunogold procedure, as follows: (a) omission of the primary anti-PGH synthase antibody; (b) substitution of irrelevant IgG of similar isotype (IgG1, MOPC21; Cappel, Malvern, PA) and concentration for the specific primary antibody; and (c) absorption of the primary PGH synthase antibody with solid support-bound, highly purified ram seminal vesicle PGH synthase (as above) before using it in the standard immunogold procedure.
Results

Mast Cells
Human lung mast cells, isolated from normal-appearing areas of lungs removed for cancer, were examined by an ultrastructural postembedding immunogold method after 6 hr in culture. Mast cells in these circumstances regularly contained a full complement of completely filled granules and many large, non-membrane-bound osmiophilic lipid bodies, as previously described (9,23-25) . Granules were membrane bound and displayed single ultrastructural patterns of scrolls, particles and, rarely, crystals, as well as mixtures of these pattems (23). Immunogold analysis with a primary PGH synthase antibody regularly revealed the presence of PGH synthase in lipid bodies (Figure 1 ); PGH synthase was absent from granules (Figure 1) and plasma membranes. (Membrane-attached ribosomes are extremely rare in human lung mast cells; such cisternae of rough endoplasmic reticulum as were present did not contain label for PGH synthase.) Three controls for specificity were negative (Figure 2) .
Alveolar Macrophages
Alveolar macrophages were regularly present in the same preparations of isolated, cultured human lung mast cells (9,24,25), thus providing another cell system for immunogold analysis of PGH synthase localization. Alveolar macrophages in these preparations contained many membrane-bound phagosomes and lysosomes, as well as non-membrane-bound, poorly osmiophilic lipid bodies (9). Immunogold staining with the primary PGH synthase antibody revealed the presence of PGH synthase in lipid bodies (Figures 3A  and 4A) ; PGH synthase was not present in lysosomes, cisternae of rough endoplasmic reticulum, or plasma membrane (Figures 3A  and 4A) , as assessed with this post-embedding immunogold technique. PGH synthase-absorbed specific primary antibody ( Figure  3B) , or an irrelevant primary antibody (Figure 4B) , showed reduced (Figure 3B ) or negative (Figure 4B ) staining of lipid bodies in alveolar macrophages.
Type 11 Alveolar Pneumocytes
Type I1 alveolar pneumocytes also were regularly present in 6-hr cultures of the isolated human lung cells. These cells are epithelial cells which contain a mixture of typical membrane-bound lamellar (surfactant) bodies and non-membrane-bound, poorly osmiophilic lipid bodies in their cytoplasm (5). Lamellar bodies typically contain concentric arrays of electron-dense membranes that are unique to Type I1 alveolar pneumocytes (5). Post-embedding immunogold stains of these cells with the primary antibody to PGH synthase revealed this enzyme in lipid bodies (Figures 5A and 6A) ; PGH synthase was absent from lamellar bodies (Figures 5A and  bB) , cisternae of rough endoplasmic reticulum (Figures 5A and 6A) , and plasma membranes ( Figure 6A) of Type I1 alveolar pneumocytes. Controls with either an irrelevant primary antibody ( Figures  5B and 6D) or PGH synthase-absorbed specific primary antibody ( Figure 6C ) were negative.
Neutrophils
Only rarely did we find typical polymorphonuclear neutrophilic granulocytes in the cultured preparations of isolated human lung cells. When present, these granulocytes retained their polylobed nuclei with condensed chromatin, were often almost devoid of their usual complement of membrane-bound secretory granules, and contained increased numbers of non-membrane-bound, poorly osmiophilic lipid bodies (2). Such activated, viable neutrophils also showed PGH synthase in cytoplasmic lipid bodies (Figure 7A) with the post-embedding immunogold method. Small numbers of gold particles were also present in the nucleus (Figure 7A) ; the cytoplasm, residual secretory granules, and plasma membrane were not labeled (membrane-attached ribosomes are extremely rare in mature neu- trophils; assessment of PGH synthase in the cisternae of these structures therefore cannot be done on these mature cells). Specificity controls with an irrelevant primary antibody (Figure 7B) or PGH synthase-absorbed specific primary antibody (data not shown) were negative.
Controls for the Immunogold Analysis
Three controls were examined as follows: (a) omission of the primary antibody from the staining sequence to show that artifactual sticking of the gold-labeled secondary antibody did not occur; (b) substitution of irrelevant antibody for the PGH synthase-specific primary antibody in the staining sequence, to demonstrate specificity of the primary antibody; (c) prior absorption of the specific primary PGH synthase antibody with solid-phase PGH synthase, also to demonstrate specificity of the primary antibody. All three controls supported the specificity of the results, i.e., omission of the primary antibody or substitution of the specific antibody with an irrelevant one resulted in negative gold staining for lipid bodies in human lung mast cells (Figure 2A and 2C) , alveolar macrophages (Figure 4B) . Type I1 alveolar pneumocytes (Figures 5B and 6D) , and neutrophils (Figure 7B) . Solid support-bound PGH synthase successfully absorbed antibody activity from the specific primary PGH synthase antibody, such that lipid body gold staining was reduced or absent in isolated human lung mast cells (Figure ZB) , alveolar macrophages (Figure 3B) . Type I1 alveolar pneumocytes (Figure 6C) , and neutrophils-all present in 6-hr cultures of isolated human lung cells. In addition, whereas specific staining of lipid bodies for PGH synthase did not occur when specific antibody was passaged through unblocked membranes, when these membranes were blocked with BSA for nonspecific protein binding sites, specific staining of lipid bodies for PGH synthase did occur. Therefore, the membrane itself did not remove specific antibody staining for PGH synthase, thereby documenting the validity of the solid-phase immunoabsorption control. 
Discussion
Important new findings regarding cytoplasmic lipid bodies and eicosanoid metabolism are presented here. Using an immunogold ultrastructural analysis, we have localized PGH synthase to lipid bodies in the cytoplasm of human lung mast cells, alveolar macrophages, Type I1 alveolar pneumocytes. and neutrophils. Prostaglan-din endoperoxide synthase (PGH synthase or cyclooxygenase) is the initial rate-limiting enzyme that acts on arachidonic acid to catalyze the formation of the prostaglandin endoperoxides that serve as the intermediates in the formation of the varied eicosanoids, prostacyclin, thromboxanes, and prostaglandins, formed by the cyclooxygenase pathway of arachidonic acid metabolism (22). Secre- Figure 3 . Human alveolar macrophages present in 6-hr cultures of isolated lung cells show gold-labeled lipid bodies (L) when exposed to anti-PGH synthase (A) that is markedly decreased when the primary antibody to PGH synthase was absorbed with PGH synthase before the immunogold procedure (e). Note that cytoplasm and plasma membrane are not labeled in A. Bars = 0.5 um.
., .-. tory (or lysosomal) granules unique to these cell types, cisternae of rough endoplasmic reticulum (when present in certain cell types, e.g., alveolar macrophages, Type I1 alveolar pneumocytes), and plasma membranes were not labeled with gold particles, indicating the absence of PGH synthase in these locations, as studied with this post-embedding immunogold technique. Appropriate specificity controls for this procedure were negative, and solid-phase PGH synthase-absorbed specific PGH synthase antibody showed appropriate reduction to the gold labeling of lipid bodies. Technical difficulties associated with retention of and/or solubilization of (and subsequent ability to label) osmiophilic human lung mast cell lipid bodies did not extend to the less osmiophilic lipid bodies of alveolar macrophages, Type I1 alveolar pneumocytes, or neutrophils. The difficulties related to human lung mast cell lipid bodies were resolved either by using freshly cut sections of human lung mast cells or by using only previously sectioned blocks if grids had been stored in oxygen-poor atmospheres in a vacuum; it is also important to pay careful attention to time and concentration in the sodium metaperiodate unmasking step which is necessary to demonstrate antigens in osmicated material. These findings support a large body of experimental evidence that now implicates non-membrane-bound cytoplasmic lipid bodies in eicosanoid metabolism in mammalian cells (reviewed in refs.  2-4) . Thus, ultrastructural autoradiographic localization of [ 3H]-AA to lipid bodies ( 6.9,10,23) . biochemical demonstration of substantial amounts of [3H]-arachidonyl-phospholipids in isolated lipid bodies (13), immunofluorescent and immunohistochemical demonstrations of prostaglandin synthase in lipid bodies within monocytes (P.F. Weller, S.W. Ryeom, unpublished data), and immunofluorescent, immunohistochemical, and ultrastructural immunogold demonstration of PGH synthase in eosinophils and fibroblasts (P.F. Weller, S.W. Ryeom, unpublished data; A.M. Dvorak et al., unpublished data) , and direct demonstrations that isolated, membrane-free fibroblast and eosinophil lipid bodies contain PGH synthase immunoreactive protein and express PGH synthase enzymatic activity (P.F. Weller, S.W. Ryeom, unpublished data) all provide evidence that lipid bodies are organelles that contain the appropriate substrates and enzymes to generate prostaglandins. More recently, highly pure, membrane-free guinea pig macrophage and hepatocarcinoma cell lipid bodies have been shown biochemically and by ultrastructural autoradiography to incorporate [ 3H]-arachidonic acid and to contain PGH synthase, as assessed by postembedding immunogold analysis (A.M. Dvorak et al., unpublished data) . Furthermore, functional studies combining biochemistry and ultrastructural autoradiography have shown release of [ 3H]-species from appropriately stimulated mast cells that were previously labeled with ['HI-AA into degranulation chambers and the supernatant fluids (11,23), and release of lipid body [3H]-AA into phagolysosomes and supernatant fluids of mouse macrophages that were actively phagocytosing zymosan (9). Moreover, the extent of release of [3H]-products, as measured biochemically in each functional circumstance, was similar to the extent of release, imaged by ultrastructural autoradiography, into newly formed degranulation chambers (11.23) or zymosan-containing phagosomes (9).
Products of arachidonic acid oxidation represent some of the most potent biologic mediators yet described, with diverse effects in inflammation, immunity, tumor biology, and hemostasis (28-35) . Despite the wealth of information available on the biochemistry and pharmacology of arachidonic acid metabolites, questions remain regarding the subcellular site(s) from which arachidonic acid is mobilized. For example, it is widely believed that phospholipids of cell membranes represent the major source of arachidonic acid entering the cyclooxygenase or lipoxygenase pathways of oxidation. However, little direct evidence exists to substantiate this claim. Several previous studies of ultrastructural pre-embedding immunoperoxidase or immunogold localization of prostaglandin H synthase in fibroblasts (27.36) or macrophages (37) and ofcyclooxygenase in rat mast cells (38) failed to demonstrate plasma membrane-associated enzyme. Similarly, our post-embedding ultrastructural immunogold analysis of four cell types (human lung mast cells, alveolar macrophages, Type I1 alveolar pneumocytes, and neutrophils) did not demonstrate plasma membrane enzyme. Therefore, in at least seven cell types with three different ultrastructural approaches, plasma membranes failed to display PGH synthase activity necessary for the production of prostaglandins from their precursor substrate, arachidonic acid. Although other ultrastructural studies localized PGH synthase to cisterns of rough endoplasmic reticulum (36) , to the nuclear membrane (36.37) of mu-rine fibroblasts (36) and human macrophages (37), or to secretory granules of rat mast cells (38) . our studies did not localize PGH synthase to these locations in the four human cells we have presented here. In contrast, cytoplasmic lipid bodies have now been shown to contain arachidonic acid ( 6,9,10,23) , specific arachidonylphospholipids (U), prostaglandin synthase enzymatic activity (P.F. Weller, S.W. Ryeom, unpublished data), and immunoreactive t Figure PGH synthase protein by light (P.F. Weller and S.W. Ryeom. unpublished data) and electron microscopic immunomorphological methods. Therefore, it is now clear that lipid bodies are uniquely constituted for the production of prostaglandins. Lipid bodies are present in a wide variety of mammalian cells (2,3,5). Their initial description in adipocytes (1) led to the recognition of these cytoplasmic organelles in a large number of circumstances (reviewed in ref. 2). For example, we have noted lipid bodies in undamaged, activated cells participating in pathobiological processes in many organ sites for years ( 5 ) . Moreover, we noted a marked increase in lipid bodies in peripheral blood cells that had migrated into tissues undergoing inflammatory or neoplastic processes. as compared with their circulating counterparts (5). Therefore, peripheral blood cells have the unique capacity to up-regulate lipid body production in circumstances known to have increased eicosanoid metabolism. This circumstantial evidence of lipid body up-regulation in vivo was considerably strengthened by the observation that lipid body formation was rapidly and specifically activated in vitro (6.7). Lipid bodies were shown to form, for example, not as an adverse reaction of cells but rather as a specific response mediated by the action of protein kinase C ( 7 ) .
Whether lipid bodies are the only phospholipid-rich cell or- ganelles involved in eicosanoid metabolism is unknown. As in many biological systems, redundancy may be present, such that phospholipid-rich intracellular and plasma membranes, as well as lipid bodies, may participate, in series or in parallel, during the generation of potent eicosanoids that are important in a wide variety of pathological conditions. With the heightened prevalence of lipid bodies characteristically found in cells associated with inflammatory responses and the demonstration that an eicosanoid-forming enzyme resides in lipid bodies, lipid bodies (and perhaps other phospholipid-rich cell structures) may have a role(s) in the formation of paracrine eicosanoid mediators of inflammation.
